Appln No.: 10/582,163
Response date June 16, 2011
Reply to Restriction Requirement of March 16, 2011

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1-38 (Cancelled).

39 (Currently Amended). A method for treatment of a psychiatric disorder, disease or condition selected from the group consisting of post-traumatic stress disorder (PTSD), depression, bipolar disorder and schizophrenia and related disorders, which comprises administering to an individual in need of such a treatment an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

40 (Currently Amended). A—The method according to claim 39, wherein said administering step comprises immunizing said individual is immunized—with a therapeutically effective amount of an—said agent—selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1—related peptide, (iii) a Copolymer 1—related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

Appln No.: 10/582,163
Response date June 16, 2011
Reply to Restriction Requirement of March 16, 2011

- 41 (Currently Amended). The method according to claim 39, wherein said agent is Copolymer 1.
- 42 (Currently Amended). The method according to claim 39, wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.
- 43 (Withdrawn/Currently Amended). The method according to claim 39, wherein said agent is T cells which have been activated by Copolymer 1.
  - 44 (Cancelled).
- 45 (Currently Amended). A—The method according to claim 44—39, wherein said psychiatric anxiety disorders disorder, disease or condition—include phobic disorders, obsessive compulsive disorder, stress, is post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder.
- 46 (Currently Amended). A—The method according to claim 45—39, wherein said psychiatric anxiety—disorder, disease or condition is post-traumatic stress disorder (PTSD) and said agent is Copolymer 1.
- 47 (Currently Amended). A—The method according to claim 44—39, wherein said psychiatric mood disorders—disorder, disease or condition include—is selected from the group consisting of depression, dysthymic disorder, and bipolar disorders—and cyclothymic disorder.

- 48 (Currently Amended). A—The method according to claim 44—39, wherein said psychiatric disorder, disease or condition is schizophrenia and said agent is Copolymer 1.
- 49 (Currently Amended). A—The method according to claim 44—39, wherein said schizophrenia related disorders include brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder.
  - 50 51 (Cancelled).
- 52 (Currently Amended). A—The method according to claim 41, wherein the Copolymer 1 is administered in the form of a vaccine.
- 53 (Currently Amended). A—The method according to claim 52, wherein said vaccine comprises Copolymer 1 without an adjuvant.
- 54 (Currently Amended). A—The method according to claim 52, wherein said vaccine comprises Copolymer 1 emulsified in an adjuvant suitable for human clinical use.
- 55 (Currently Amended). A—The method according to claim 54, wherein said adjuvant is aluminum hydroxide, aluminum hydroxide gel or aluminum hydroxyphosphate.